RxDoctor Payments Data

Michelle Richardson

Family · Wilmington, NCNPI 1194918052

Payments from drug & device makers

$749in general payments, 2019–2025

Across 44 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$173
  • AbbVie$96
  • Biohaven Pharmaceutical Holding Company Ltd.$80
  • Amgen$77
  • Abbott$65
  • GSK$41
  • plus $217 from 13 others

What the payments were for

  • Food & beverage$749100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$749 in reported general payments places this provider in the 65th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$80,670
Medicare patients
291
Services billed
1,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide41$43,565
JardianceEmpagliflozin57$43,390
OzempicSemaglutide33$40,747
UbrelvyUbrogepant16$18,797
Breo ElliptaFluticasone/Vilanterol28$16,982
XareltoRivaroxaban22$12,197
SynthroidLevothyroxine Sodium76$6,280
JanuviaSitagliptin Phosphate12$6,230
SymbicortBudesonide/Formoterol Fumarate11$5,144
PremarinEstrogens, Conjugated17$4,228
PaxlovidNirmatrelvir/Ritonavir20$4,226
VyvanseLisdexamfetamine Dimesylate11$4,124
Tolterodine Tartrate ErTolterodine Tartrate19$2,944
Levothyroxine Sodium286$2,408
Atorvastatin Calcium235$2,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$13$43,56541 claims
Novo NordiskOzempic$173$40,74733 claims
AbbVieUbrelvy, Synthroid$96$25,07792 claims
GSKBreo Ellipta$41$16,98228 claims
Johnson & JohnsonXarelto$25$12,19722 claims
AstraZenecaSymbicort$21$5,14411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,522 family providers in North Carolina.

Other family in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →